Corcept Therapeutics (CORT)
Corcept Therapeutics Statistics
Share Statistics
Corcept Therapeutics has 105.5M shares outstanding. The number of shares has increased by 1.34% in one year.
| Shares Outstanding | 105.5M |
| Shares Change (YoY) | 1.34% |
| Shares Change (QoQ) | 0.69% |
| Owned by Institutions (%) | 81.5% |
| Shares Floating | 93.22M |
| Failed to Deliver (FTD) Shares | 33 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 16.04M, so 15.21% of the outstanding shares have been sold short.
| Short Interest | 16.04M |
| Short % of Shares Out | 15.21% |
| Short % of Float | 17.21% |
| Short Ratio (days to cover) | 12.28 |
Valuation Ratios
The PE ratio is 37.23 and the forward PE ratio is 19.67. Corcept Therapeutics's PEG ratio is 1.15.
| PE Ratio | 37.23 |
| Forward PE | 19.67 |
| PS Ratio | 7.71 |
| Forward PS | 3 |
| PB Ratio | 7.65 |
| P/FCF Ratio | 26.55 |
| PEG Ratio | 1.15 |
Enterprise Valuation
Corcept Therapeutics has an Enterprise Value (EV) of 5.08B.
| EV / Sales | 7.53 |
| EV / EBITDA | 37.1 |
| EV / EBIT | 25.65 |
| EV / FCF | 25.94 |
Financial Position
The company has a current ratio of 3.35, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.35 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.05 |
| Debt / FCF | 0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 20.56% and Return on Invested Capital is 17.09%.
| Return on Equity | 20.56% |
| Return on Assets | 16.62% |
| Return on Invested Capital | 17.09% |
| Revenue Per Employee | $1.35M |
| Profits Per Employee | $279.47K |
| Employee Count | 500 |
| Asset Turnover | 0.8 |
| Inventory Turnover | 0.88 |
Taxes
| Income Tax | 20.28M |
| Effective Tax Rate | 12.56% |
Stock Price Statistics
The stock price has increased by 197.65% in the last 52 weeks. The beta is 0.14, so Corcept Therapeutics's price volatility has been higher than the market average.
| Beta | 0.14 |
| 52-Week Price Change | 197.65% |
| 50-Day Moving Average | 65.4 |
| 200-Day Moving Average | 50.48 |
| Relative Strength Index (RSI) | 49.3 |
| Average Volume (20 Days) | 1.52M |
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 675.04M and earned 139.73M in profits. Earnings per share was 1.35.
| Revenue | 675.04M |
| Gross Profit | 664.16M |
| Operating Income | 136.95M |
| Net Income | 139.73M |
| EBITDA | 136.95M |
| EBIT | 136.95M |
| Earnings Per Share (EPS) | 1.35 |
Balance Sheet
The company has 127.67M in cash and 6.94M in debt, giving a net cash position of 120.73M.
| Cash & Cash Equivalents | 127.67M |
| Total Debt | 6.94M |
| Net Cash | 120.73M |
| Retained Earnings | 543.74M |
| Total Assets | 840.55M |
| Working Capital | 330.83M |
Cash Flow
In the last 12 months, operating cash flow was 198.07M and capital expenditures -2.17M, giving a free cash flow of 195.9M.
| Operating Cash Flow | 198.07M |
| Capital Expenditures | -2.17M |
| Free Cash Flow | 195.9M |
| FCF Per Share | 1.9 |
Margins
Gross margin is 98.39%, with operating and profit margins of 20.29% and 20.7%.
| Gross Margin | 98.39% |
| Operating Margin | 20.29% |
| Pretax Margin | 23.92% |
| Profit Margin | 20.7% |
| EBITDA Margin | 20.29% |
| EBIT Margin | 20.29% |
| FCF Margin | 29.02% |
Dividends & Yields
CORT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.69% |
| FCF Yield | 3.77% |
Analyst Forecast
The average price target for CORT is $146, which is 109.7% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $146 |
| Price Target Difference | 109.7% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 29.35 |
| Piotroski F-Score | 5 |